A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95700
Title:
A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
Authors:
Weaver, Andrew; Wrigley, E; Watson, A; Chang, James; Collins, Conor D; Jenkins, B; Gill, C; Pettengell, Ruth; Dexter, T Michael; Testa, Nydia G; Crowther, Derek
Abstract:
We have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclophosphamide chemotherapy in previously untreated patients with ovarian cancer. These cells may be used to provide safe and effective haemopoietic rescue following dose-intensive chemotherapy. Using filgrastim alone (10 micrograms kg-1), the apheresis harvest contained a median CFU-GM count of 45 x 10(4) kg-1 and 2 x 10(6) kg-1 CD34+ cells. Treatment with filgrastim (5 micrograms kg-1) following cyclophosphamide (3 g m-2) resulted in a harvest containing 66 x 10(4) kg-1 CFU-GM and 2.4 x 10(6) kg-1 CD34+ cells. There was no statistically significant difference between these two mobilising regimens. We have also demonstrated that dose-intensive carboplatin and cyclophosphamide chemotherapy can be delivered safely to patients with ovarian cancer when supported by peripheral blood progenitor cells and filgrastim. Carboplatin (AUC 7.5) and cyclophosphamide (900 mg m-2) given at 3 weekly intervals with progenitor cell and growth factor support was well tolerated in terms of haematological and systemic side-effects. Double the dose intensity of chemotherapy was delivered compared with our standard dose regimen when the treatment was given at 3 weekly intervals. Median dose intensity could be further escalated to 2.33 compared with our standard regimen by decreasing the interval between treatment cycles to 2 weeks. However, at this dose intensity less than a third of patients received their planned treatment on time. All the delays were due to thrombocytopenia.
Affiliation:
Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. 1996, 74 (11):1821-7 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Dec-1996
URI:
http://hdl.handle.net/10541/95700
PubMed ID:
8956800
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWeaver, Andrewen
dc.contributor.authorWrigley, Een
dc.contributor.authorWatson, Aen
dc.contributor.authorChang, Jamesen
dc.contributor.authorCollins, Conor Den
dc.contributor.authorJenkins, Ben
dc.contributor.authorGill, Cen
dc.contributor.authorPettengell, Ruthen
dc.contributor.authorDexter, T Michaelen
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-04-06T11:24:10Z-
dc.date.available2010-04-06T11:24:10Z-
dc.date.issued1996-12-
dc.identifier.citationA study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. 1996, 74 (11):1821-7 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid8956800-
dc.identifier.urihttp://hdl.handle.net/10541/95700-
dc.description.abstractWe have shown that large numbers of haemopoietic progenitor cells are mobilised into the blood after filgrastim [granulocyte colony-stimulating factor (G-CSF)] alone and filgrastim following cyclophosphamide chemotherapy in previously untreated patients with ovarian cancer. These cells may be used to provide safe and effective haemopoietic rescue following dose-intensive chemotherapy. Using filgrastim alone (10 micrograms kg-1), the apheresis harvest contained a median CFU-GM count of 45 x 10(4) kg-1 and 2 x 10(6) kg-1 CD34+ cells. Treatment with filgrastim (5 micrograms kg-1) following cyclophosphamide (3 g m-2) resulted in a harvest containing 66 x 10(4) kg-1 CFU-GM and 2.4 x 10(6) kg-1 CD34+ cells. There was no statistically significant difference between these two mobilising regimens. We have also demonstrated that dose-intensive carboplatin and cyclophosphamide chemotherapy can be delivered safely to patients with ovarian cancer when supported by peripheral blood progenitor cells and filgrastim. Carboplatin (AUC 7.5) and cyclophosphamide (900 mg m-2) given at 3 weekly intervals with progenitor cell and growth factor support was well tolerated in terms of haematological and systemic side-effects. Double the dose intensity of chemotherapy was delivered compared with our standard dose regimen when the treatment was given at 3 weekly intervals. Median dose intensity could be further escalated to 2.33 compared with our standard regimen by decreasing the interval between treatment cycles to 2 weeks. However, at this dose intensity less than a third of patients received their planned treatment on time. All the delays were due to thrombocytopenia.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cellsen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBlood Component Removal-
dc.subject.meshCarboplatin-
dc.subject.meshCyclophosphamide-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshDrug Eruptions-
dc.subject.meshFemale-
dc.subject.meshFever-
dc.subject.meshFilgrastim-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeutropenia-
dc.subject.meshOvarian Neoplasms-
dc.titleA study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.